MARKET

VLON

VLON

Vallon Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.54
+0.52
+7.41%
Closed 16:00 09/24 EDT
OPEN
6.93
PREV CLOSE
7.02
HIGH
7.79
LOW
6.90
VOLUME
121.38K
TURNOVER
--
52 WEEK HIGH
10.36
52 WEEK LOW
3.610
MARKET CAP
46.57M
P/E (TTM)
-6.4632
1D
5D
1M
3M
1Y
5Y
BRIEF-Vallon Pharmaceuticals Reports Formation Of Scientific Advisory Board
reuters.com · 09/14 12:52
Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board
Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse
Benzinga · 09/14 12:14
Shares of Vallon Pharmaceuticals Inc. (VLON) Exceed 52-Week High
(MENAFN - Investor Brand Network) Shares of Vallon Pharmaceuticals Inc. (NASDAQ:VLON) traded today at $10.20, eclipsing its 52-week high. This new high was reached on above average trading volume as 535,000 shares traded hands, while the average 30-day v...
MENAFN · 09/10 19:23
ACST, AMSC and NETE among mid-day movers
Gainers: Regional Health Properties (NYSE:RHE) +55%. AC Immune (NASDAQ:ACIU) +34%. Net Element (NASDAQ:NETE) +27%. Vallon Pharmaceuticals (NASDAQ:VLON) +25%. Spok (NASDAQ:SPOK) +23%. Elys Game Technology (NASDAQ:ELYS) +21%. Youdao (NYSE:DAO) +20%. Qualigen
Seekingalpha · 08/31 16:54
60 Biggest Movers From Yesterday
Gainers Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 80.9% to close at $5.30 on Friday. The company recently reported a Q2 loss of $5.13 per share.
Benzinga · 08/30 09:18
Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit
Live video webcast with David Baker, President and CEO of Vallon, on Wednesday, August 18th 12:30 PM ET PHILADELPHIA, PA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharma...
GlobeNewswire · 08/11 12:05
Vallon Pharmaceuticals Q2 Net Loss $2.3M
Vallon Pharmaceuticals (NASDAQ:VLON) will report on Q2 2021.
Benzinga · 08/10 12:10
BRIEF-Vallon Pharmaceuticals Reports Q2 Results
reuters.com · 08/10 12:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VLON. Analyze the recent business situations of Vallon Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VLON stock price target is 12.00 with a high estimate of 12.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 11
Institutional Holdings: 579.29K
% Owned: 9.38%
Shares Outstanding: 6.18M
TypeInstitutionsShares
Increased
2
7.99K
New
5
238.85K
Decreased
1
138.56K
Sold Out
4
55.48K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About VLON
Vallon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is primarily focused on the development and commercialization of proprietary biopharmaceutical products. It is focused on developing prescription drugs for central nervous system (CNS) disorders. Its clinical-stage product is Abuse-Deterrent Amphetamine Immediate-Release (ADAIR), an abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. It also intends to develop other abuse-deterrent products, including the development of an abuse deterrent formulation of Ritalin (ADMIR). ADAIR is being designed as a formulation that resists manipulation and preparation for snorting and provides meaningful barriers to injection. ADMIR is designed to have abuse deterrent properties that are similar to ADAIR.

Webull offers kinds of Vallon Pharmaceuticals Inc stock information, including NASDAQ:VLON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VLON stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VLON stock methods without spending real money on the virtual paper trading platform.